Simplify Logo

Full-Time

Sr. Manager

Supply Chain Planning

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulation therapies for diseases

Hardware
Biotechnology

Compensation Overview

$165k - $185kAnnually

Senior

Menlo Park, CA, USA

Category
Supply Chain Management
Operations & Logistics
Required Skills
Communications
PowerPoint/Keynote/Slides
Requirements
  • Working experience with global clinical trials and IRT systems
  • Working knowledge of cGMPs and familiarity with US and EU regulations
  • Working knowledge of drug development process (Phase I-IV)
  • Excellent interpersonal, verbal, and written communication skills
  • Excellent organizational skills and ability to prioritize effectively
  • Strong attention to detail with excellent follow-up
  • Proficient in Microsoft Outlook, Word, Excel, PowerPoint
Responsibilities
  • Develop supply plans for all Corcept clinical studies
  • Perform scenario planning to support decision-making
  • Provide clinical supply and risk mitigation recommendations
  • Oversee inventory management of study drug and comparators at depots
  • Maintain supply dashboards and KPIs
  • Work cross-functionally to ensure supply plans are feasible
  • Provide product costs to support international shipments
  • Develop and implement appropriate Supply Chain SOPs

At Corcept Therapeutics, we specialize in pioneering selective glucocorticoid receptor antagonists. Our focused efforts extend to over 30 active studies aimed at addressing the detrimental impacts of excess cortisol in endocrine, metabolic, oncologic, and psychiatric conditions. We are dedicated not only to advancing medical science but also to prioritizing the well-being of our team, ensuring a collaborative and supportive work environment that fosters innovation and professional growth.

Company Stage

IPO

Total Funding

$119.1M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

4%

1 year growth

10%

2 year growth

34%